Reference

L-Carnitine chloride formulations for treatment of cardiopathy

L-Carnitine chloride formulations for treatment of cardiopathy. (Earth Chemical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 59222412 A2 14 Dec 1984 Showa, 9 pp. (Japanese). (Japan). CODEN: JKXXAF. CLASS: ICM: A61K031-195. APPLICATION: JP 83-97511 1 Jun 1983. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 Pharmaceuticals contain L-carnitine chloride [6645-46-1] for treatment of heart failure, arrhythmia, angina pectoris, etc. Thus, a mixt. comprising cryst. cellulose 10, Mg stearate 0.4, talc 0.8, and carnitine chloride 20 ~ 50 parts of wt. was encapsulated. L-Carnitine chloride (300 mg/kg, s.c.) given to rats with isoproterenol-induced heart failure showed therapeutic effects.

L-Carnitine and its intermediate products

L-Carnitine and its intermediate products. Sih, Charles J. (Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy). Belg. BE 898396 A1 30 Mar 1984, 38 pp. (French).Some commonly used reagents like 90836-01-4 is used in this experiment. (Belgium). CODEN: BEXXAL. ICI: C12. APPLICATION: BE 21-2 6 Dec 1983. PRIORITY: US 82-447171 6 Dec 1982; US 83-544957 21 Oct 1983. DOCUMENT TYPE: Patent CA Section: 16 (Fermentation and Bioindustrial Chemistry) L-Carnitine [541-15-1] is prepd. from g-substituted amides or esters of acetoacetic acid by a stereospecific microbial redn. followed by chem. derivatization steps. Thus, g-chloroacetoacetic acid octyl ester [41051-21-2] in Tween 80 was added to an actively growing culture of Candida kefyr and incubated for 24 h. The product, 4-chloro-3(R)-hydroxybutyric acid octyl ester (I) [86728-99-6], was isolated from the broth supernatant in ~70% yield by chromatog. on silica gel. I (1.5 g) was heated with Me3N [75-50-3] in 3 mL EtOH for 2 h to yield a solid that was heated in 10% HCl at 80-90° for 1.5 h. After evapn. of the solvents, 320 mg L-carnitine chloride [6645-46-1] was extd. from the residue with EtOH and pptd. with ether. .